Day Two

• Examine the potential of trispecific T-cell engagers TCEs and bispecific ADCs as next-generation strategies for deep B-cell depletion across oncology and autoimmune indications
• Understand the mechanistic advantages of multi-specific modalities in enhancing precision, potency, and durability compared to traditional approaches
• Explore translational insights and early data shaping the clinical promise of these innovative platforms for redefining treatment paradigms

• Understanding the data needed to establish evidence-based guidelines for revaccination timing and efficacy following deep B-cell depletion
• Establishing a framework for determining the appropriate risk threshold for autoimmune patients to undergo deep B-cell depletion
• Defining long-term surveillance markers to monitor the safety of B-cell depletion therapies using longitudinal immune monitoring data

• Discussing the emerging clinical data showing deep, sustained B-cell depletion in Lupus patients
• Exploring whether depth of depletion translates into long-term, drug-free remission that has been unattainable with conventional treatments
• Identifying signatures in the repopulating B-cell and T-cell compartments that predict durable remission and guide the regulatory pathway for a curative therapy

Join this session for a candid conversation with experts pursuing the reality of of-the-shelf cell therapies:

• Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
• Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
• Deep diving into current indications being explored for allogeneic cell therapy

• HB2198 is an anti-CD19/CD20 bispecific antibody with dual enhanced Fc domains created with Hinge Bio’s GEM-DIMER™ technology
• HB2198 exhibits potent B-cell depletion in vitro, demonstrating ADCC, ADCP, CDC and direct killing
• HB2198 rapidly depletes B-cells and results in durable remodeling of the B-cell compartment in cynomolgus monkeys with no cytokine release up to 25 mg/kg. Preparations for Phase 1 clinical trial in SLE/LN ongoing

• Discussing why B-cell targeted therapies alone is often insufficient
• Emphasizing the need to break the T/B-cell axis to modulate T-helper cells that provide survival and differentiation signals for pathogenic B-cells
• Defining the necessary therapeutic precision, selective manipulation or depletion of pathogenic T-cell subsets while preserving the protective, conventional T-cell immunity

• Developing orally delivered immune biomodulators that selectively reprogram dendritic cells within the gut mucosa to drive systemic immune resetting
• Demonstrating how targeted conditioning of intestinal dendritic cells induces tolerogenic pathways, restores regulatory T-cell activity, and exerts downstream control of B-cell hyperactivation
• Summarizing key preclinical and emerging clinical findings, discuss platform design principles, and outline how oral immune therapies can provide safer, more durable, and more accessible treatment options for autoimmune and inflammatory diseases

• Highlighting the ability of BCMA T-cell engagers to induce the broad depletion of peripheral and tissue B-cells
• Analyzing the utility of BCMA targeting as a modality to eliminate long-lived plasma cells which can survive CD20 and CD19 depletion
• Discuss the pros and cons of targeting BCMA vs other B-cell targets

Join this session for a candid conversation around the future of T-cell depletion for immune reset:

• Debating the technical feasibility and current limitations of logic-gated CAR-T cells in autoimmunity
• Discussing the emerging paradigm of T-cell modulation vs elimination including the modalities most promising for safely silencing autoreactive T-cells without long-term safety risks
• Effectively measuring the resulting state of functional tolerance
• Exploring the combination of translational biomarkers and clinical trial endpoints necessary to validate the safety and disease specificity of targeted T-cell therapies